Innovative non-surgical treatment for presbyopia

Article

Ophthalmic drops for presbyopes to be introduced

Presbyopia occurs without regard to other eye conditions. The smooth ciliary body muscles pull and push the lens, adjusting its curvature, and thereby adjusting the eye's focal power to bring objects into focus. As individuals age, the lens becomes stiffer, more resilient to flexure , and the muscular activity in the ciliary body become less powerful. Because these changes result in inadequate adjustment of the lens of the eye for various distances, objects that are close will appear blurry. The major cause of presbyopia is loss of elasticity of the lens of the eye. Loss of ciliary muscle power, however, is also believed to contribute to the problem.

Incurable problem

Bifocal contact lenses are similar to bifocal glasses but with limited success. The top portion of the lens serves as the distance lens while the lower serves as the near vision lens. To prevent rotation while in the eye, bifocal contacts use a specially manufactured type of lens. Good candidates for bifocal lenses are those patients who have a good tear film (moist eyes), good binocular vision (ability to focus both eyes together) and visual acuity in each eye, and no disease or abnormalities in the eyelids.

Multifocal contacts tend to either extend the range of acceptable vision from far to near or provide images of distant and near objects simultaneously over the macula. Many of these contact lens designs have been around for more than half a century.

A third alternative is refractive surgery for presbyopia either by a specific laser paradigm or by refractive lens exchange - replacing the natural lens with a bi- or multifocal intraocular lens.

A fourth alternative is now about to be introduced to the wider public. Presbyeyedrops - Método Benozzi is a medical treatment to correct presbyopia by means of ophthalmic drops. It is a pharmacological treatment for presbyopia that avoids the use of eye glasses, contacts or invasive surgery. It consists of an ophthalmic drop patented by Dr Jorge Benozzi which contains a combination of two drugs: a parasympathomimetic and a nonsteroid antiinflammatory agent. Together, they both act on the ciliary muscle responsible for the necessary changes of the lens in accommodation (or focus).

During his research on the drops for presbyopia, Dr Benozzi investigated the causes of this disease, and found that one cause is related to the progressive decrease in the production of the neurotransmitter responsible for the stimulation of the ciliary muscle in the human eye. By means of this drop, the eye is kick-started, provided with that neurotransmitter that the system stopped producing and in the necessary amount; thereby compensating this deficiency and recovering the compromised near vision.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.